Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Express Scripts
McKesson
McKinsey
Boehringer Ingelheim

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,144,577

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,144,577 protect, and when does it expire?

Patent 7,144,577 protects EGRIFTA and is included in one NDA.

Summary for Patent: 7,144,577
Title:Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
Abstract:Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDS and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.
Inventor(s): Torres; Ramon A. (New York, NY)
Assignee: Applied Research Systems ARS (Curacao, NL)
Application Number:10/725,484
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,144,577

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes   Start Trial   Start Trial REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY   Start Trial
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes   Start Trial   Start Trial REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Merck
Express Scripts
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.